Oppenheimer & Co’s IN8bio INAB Stock Holding History

Oppenheimer & Co’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-63,042	Closed	-$88.9K	–	1805
2026 Q2	$88.9K	Buy	63,042 +39,009	+162%	+$58.8K	﹤0.01%	1725
2026 Q1	$35.6K	Buy	+24,033	New	+$46.5K	﹤0.01%	1672

Other funds holding INAB

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Oppenheimer & Co's INAB Position: Q3 2026 in Review

Oppenheimer & Co sold out of IN8bio (INAB) in Q3 2026, closing a stake of 63,042 shares — an estimated $88.9K sold.

Oppenheimer & Co first reported a position in INAB in Q1 2026 and held it in 2 quarters. The position peaked at $88.9K in Q2 2026. 2 funds tracked by Wall St. Rank hold INAB as of Q3 2026.

Oppenheimer & Co reported no remaining IN8bio position as of Q3 2026 after selling out during the quarter.
Oppenheimer & Co sold 63,042 IN8bio shares in Q3 2026, an estimated $88.9K.
Oppenheimer & Co first reported a position in IN8bio in Q1 2026 and held it in 2 quarters.
Oppenheimer & Co's IN8bio position peaked at $88.9K in Q2 2026.
2 funds tracked by Wall St. Rank held IN8bio as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.